Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
120
datasets available to search
ShareScore release 0.9.0
Dataset results
120 results for “cutaneous melanoma”
autologous pairs of cutaneous melanocyte and melanoma cell cultures
GEO Series GSE38312. Homo sapiens. 10 samples. Type: Expression profiling by array.
Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in Stage IV cutaneous malignant melanoma
GEO Series GSE102166. Homo sapiens. 53 samples. Type: Other.
Metformin Regulates Ferroptosis in Skin Cutaneous Melanoma
GEO Series GSE280924. Homo sapiens. 9 samples. Type: Expression profiling by high throughput sequencing.
COMMD4, a novel driver for skin cutaneous melanoma progression via targeting p85 to activate PI3K/Akt signaling
GEO Series GSE298192. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma
GEO Series GSE45266. Homo sapiens. 29 samples. Type: Methylation profiling by array.
RNA-seq profiling of PRAME knockdown in A375SM skin cutaneous melanoma cells
GEO Series GSE311500. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Altitude effect on cutaneous melanoma epidemiology in the Veneto Region (Northern Italy): a pilot study.
<p>The incidence of cutaneous melanoma has been increasing in the last decades among fair-skinned population. Despite complex and multifactorial etiology, the exposure to ultraviolet radiation (UVR) is the most consistent modifiable risk factor for melanoma. Several factors influence the amount of UVR reaching Earth’s surface. Our study aimed to explore the relationship between melanoma and altitude in an area with mixed geographic morphology, such as the Veneto region (Italy). We included 2,752 melanoma patients who were referred to our centers between 1998 and 2014. Demographics, histological and clinical data, and survival information were extracted from a prospectively maintained local database. Head/neck and acral melanoma were more common in patients from the hills and the mountains, while limb and trunk melanoma were more common in patients living in plain and coastal areas. Breslow thickness, ulceration and mitotic rate impaired with increased altitude. However, geographical area of origin was not associated with overall or disease-free survival. Geographical area of origin of melanoma patients and the “coast-plain-hill gradient” could help to estimate the influence of different sun exposure and to explain the importance of vitamin D level in skin-cancer control .</p>
Role of DNA methylation in the regulation of SLC22A17 in cutaneous melanoma. Identification of SLC22A17 methylation hotspot as potential epigenetic biomarker
<p><strong><br>Authors: Alessandro Lavoro; Luca Falzone; <span><span>Giuseppe Gattuso; Giuseppe Nicolò Conti; Rosario Caltabiano;</span></span> Gabriele Madonna; Mariaelena Capone; James Andrew McCubrey; Paolo Antonio Ascierto; Massimo Libra; Saverio Candido<br>Corresponding author: Dr Massimo Libra</strong></p> <p><strong>Abstract </strong></p> <p>Cancer onset and progression are driven by genetic and epigenetic alterations leading to oncogene activation and silencing of tumor suppressor genes. Among epigenetic mechanisms, DNA methylation (methDNA) has attracted growing interest in cancer research, playing a critical role in the regulation of gene expression. As widely reported, promoter hypomethylation is strictly associated with tumor-related gene activation. Moreover, the intragenic methDNA is involved in transcriptional elongation, alternative spicing, and activation of cryptic start sites. However, the exact role of intragenic methDNA has not been completely elucidated yet. In this context, several tumor microenvironment genes are modulated by methDNA, including the <em>Solute Carrier Family 22 Member 1</em>7 (<em>SLC22A17</em>), which is involved along with the <em>Gelatinase-Associated Lipocalin</em> (<em>NGAL</em>) ligand in iron trafficking and extracellular matrix remodeling.</p> <p>On these bases, this study aimed to investigate the role of methDNA in the regulation of <em>SLC22A17</em> in cutaneous melanoma (CM). To this purpose, correlation and differential analyses between <em>SLC22A17</em> expression and methDNA levels in CM patients and nevi samples were performed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Functional studies on melanoma cell lines treated with 5-Azacytidine (5-Aza) were conducted to assess the correlation between methDNA and <em>SLC22A17</em> expression. Validation study was finally performed analyzing the <em>in silico</em> identified <em>SLC22A17</em> methDNA hotspot in Formalin-Fixed Paraffin-Embedded (FFPE) samples from a consecutive cohort of CM patients and healthy controls to test its potential application as a diagnostic and prognostic biomarker. The FFPE tissues were collected at the Melanoma Cancer Immunotherapy and Innovative Therapy Unit of the National Cancer Institute ‘Fondazione ‘G. Pascale’ (Naples, Italy), retrospectively retrieving the FFPE samples from the archives of the Pathology Unit (years 2008 – 2020) . The study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the National Cancer Institute “Fondazione G. Pascale” (protocol n. 33/17 and 37/22 oss). </p> <p>The computational analyses revealed that <em>SLC22A17</em> was significantly downregulated in CM and its expression levels were strictly related to promoter hypomethylation and body hypermethylation. Moreover, <em>SLC22A17</em> overexpression, as well as hypermethylation of 2 intragenic methDNA hotspots, were associated with a better clinical outcome in CM patients. The correlation between <em>SLC22A17</em> methDNA and expression was confirmed in 5-Aza treated cell lines. In agreement with <em>in silico</em> analyses, the selected <em>SLC22A17 </em>hotspot showed higher methDNA levels in CM samples compared to nevi. In addition, the methDNA levels of this hotspot were positively correlated with advanced CM.</p> <p>Overall, the <em>SLC22A17</em> methDNA hotspot could represent a promising biomarker for CM, highlighting the regulatory role of methDNA on <em>SLC22A17</em> expression. In conclusion, these results pave the way to the identification of novel epigenetic biomarkers and therapeutic targets for the management of CM patients.</p> <p><strong> </strong></p>
RNA transcriptome sequencing of Skin Cutaneous Melanoma cell line A375 and SK-MEL-28 treated with siNC or siLINC01291
GEO Series GSE285702. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
Bi-directional regulation between NAD/NAMPT and IFN-γ/PD-L1 axes via BRD4/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma
GEO Series GSE310354. Homo sapiens. 9 samples. Type: Expression profiling by high throughput sequencing.
Identification of distinct molecular signatures in BRAF V600E and BRAF wt cutaneous melanomas
GEO Series GSE22838. Homo sapiens. 18 samples. Type: Expression profiling by array.
PURPL Represses Radiation-induced Apoptosis to Promote Radioresistance in Cutaneous Melanoma by Direct Interfering with BID Cleavage
GEO Series GSE248024. Homo sapiens. 2 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Gene expression profile of murine cutaneous melanoma after systemic treatment with tumor necrosis factor (TNF) associated or not with melphalan (MEL).
GEO Series GSE21559. Mus musculus. 36 samples. Type: Expression profiling by array.
Transcriptome sequencing analysis of GADD45B and HOPX gene overexpression in human cutaneous melanoma
GEO Series GSE221101. Homo sapiens. 9 samples. Type: Expression profiling by high throughput sequencing.
Skin Cutaneous Melanoma Broad
Whole-exome sequencing of 121 melanoma samples with matched normals. The cases here are only those under the age of 40 years old.
Cutaneous Melanoma in Alpine Population: Incidence Trends and Clinicopathological Profile
<p>Previous studies associated high-level exposure to ultraviolet radiation with a greater risk of cutaneous malignant melanoma (CMM). This study focuses on the changing incidence of CMM over time (from 1990 to 2017) in the Veneto region of Northeast Italy, and its Alpine area (the province of Belluno). The clinicopathological profile of CMM by residence is also considered. A joinpoint regression analysis was performed to identify significant changes in the yearly incidence of CMM by sex and age. For each trend, the average annual percent change (AAPC) was also calculated. In the 2017 CMM cohort, the study includes a descriptive analysis of the disease's categorical clinicopathological variables. In the population investigated, the incidence of CMM has increased significantly over the last 30 years. The AAPC in the incidence of CMM was significantly higher among Alpine residents aged 0-49 than for the rest of the region's population (males: 6.9 versus 2.4; females 7.7 versus 2.7, respectively). Among the Alpine residents, the AAPC was 3.35 times greater for females aged 0-49 than for people aged 50+. The clinicopathological profile of CMM was significantly associated with the place of residence. Over three decades, the Veneto population has observed a significant increase in the incidence of CMM, and its AAPC. Both trends have been markedly more pronounced among Alpine residents, particularly younger females. While epidemiology and clinicopathological profiles support the role of UV radiation in CMM, the young age of this CMM-affected female population points to other possible host-related etiological factors. These findings also confirm the importance of primary and secondary prevention strategies.</p>
Sex Differences in Cutaneous Melanoma: Incidence, Clinicopathological Profile, Survival, and Costs
<p>This study aims to provide a comprehensive overview of sex-related characteristics of cutaneous malignant melanoma (CMM), with special reference to its incidence, clinicopathological profile, overall survival, and treatment-related costs. This retrospective cohort study included all 1,279 CMM patients who were registered in 2015 in the Veneto Cancer Registry (a population-based registry including all 4,900,000 regional residents). The by-sex comparisons included tumor stage and site, histological subtype, and other clinical-pathological variables. A Cox regression analysis was used to test the association between sex and survival, adjusting for the main covariates. Treatment costs were calculated by linking patients with several administrative regional databases. Age-specific incidence rates were significantly higher for men among people >50 years old. For men, the trunk was the most common primary site (59.3%), whereas for women the lower limbs (32.1%) were the most common primary site, followed by the trunk (31.8%), which was lower than for men (<em>p</em> < 0.001). At presentation, the frequency of early stage CMM was higher among women, who also featured a significantly lower risk of death (<em>p</em> = 0.016), after adjusting for covariates. Men also incurred higher costs for melanoma treatment in the first year after their diagnosis. Among younger adults, CMM was more common in women, whereas among older adults, it was more common in men. Sex also influences patients' histopathological characteristics at diagnosis. Women had better overall survival after adjusting for demographic, pathological, and clinical profiles. The costs of treatment were also lower for women with CMM.</p>
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective
<p>The prognosis of cutaneous malignant melanoma (CMM) is based on disease progression. The highly heterogeneous clinical-pathological characteristics of CMM necessitate standardized diagnostic and therapeutic interventions tailored to cancer's stage. This study utilizes clinical performance indicators to assess the quality of CMM care in Veneto (Northeast Italy). This population-based study focuses on all incidences of CMMs registered by the Veneto Cancer Registry in 2015 (1279 patients) and 2017 (1368 patients). An interdisciplinary panel of experts formulated a set of quality-monitoring indicators for diagnostic, therapeutic, and end-of-life clinical interventions for CMM. The quality of clinical care for patients was assessed by comparing the reference thresholds established by experts to the actual values obtained in clinical practice. The prevalence of stage I-CMM decreased significantly from 2015 to 2017 (from 71.8 to 62.4%; P < 0.001), and almost all the pathology reports mentioned the number of nodes dissected during a lymphadenectomy. More than 90% of advanced CMMs were promptly tested for molecular BRAF status, but the proportion of patients given targeted therapies fell short of the desired threshold (61.1%). The proportion of stage I-IIA CMM patients who inappropriately underwent computerized tomography/MRI/PET dropped from 17.4 to 3.3% ( P < 0.001). Less than 2% of patients received medical or surgical anticancer therapies in the month preceding their death. In the investigated regional context, CMM care exhibited both strengths and weaknesses. The evaluated clinical indicators shed essential insight on the clinical procedures requiring corrective action. It is crucial to monitor clinical care indicators to improve care for cancer patients and promote the sustainability of the healthcare system.</p>
The metastatic microenvironment. Brain-derived soluble factors alter the malignancy phenotype of cutaneous and brain- metastasizing melanoma cells
GEO Series GSE34970. Homo sapiens. 4 samples. Type: Expression profiling by array.
The role of CDK7 in cutaneous melanoma
GEO Series GSE158125. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.